Buy & Sell Bristol-Myers Squibb Co (BMY) – Bristol-Myers Squibb Co Price Today
Aura AI Summary
Key Stats
- $116.95BMarket Cap
- HealthSector
- -11.78%3M Drawdown
- $152.89BEnterprise Value
- 4.4%Dividend Yield
- 91 daysTypical Hold Time
Bristol-Myers Squibb Co (BMY) is currently valued at a market capitalization of $116.95B, with an enterprise value of $152.89B. Over the past 52 weeks, Bristol-Myers Squibb Co has traded between a low of $42.6 and a high of $62.37, highlighting its annual price range. Over the past three months, Bristol-Myers Squibb Co has recorded a drawdown of -11.78%, reflecting recent price volatility. Bristol-Myers Squibb Co offers a dividend yield of 4.4%, with the most recent dividend of $0.63 paid on 02 Apr 26. On average, investors hold Bristol-Myers Squibb Co for approximately 91 days, indicating typical investor behavior on the platform.
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Most Recent News
Public Storage shows weak growth and refinancing risks; Outfront Media shines with strong earnings and dividend.
Public Storage's Q1 earnings were boosted by a foreign currency gain, masking underlying declines in revenue and occupancy, with full-year 2026 guidance showing flat to negative growth and a significant debt refinancing challenge amid high interest r...

Ascletis Pharma showcases promising oral obesity treatments at ADA 2026, advancing key drug candidates.
Ascletis Pharma presented three key studies at the ADA 2026 Scientific Sessions highlighting its innovative oral treatments for obesity, including ASC39, ASC30, and ASC37. ASC39 showed potent, selective weight loss effects in animal models, ASC30 dem...

Wegovy pill hits 3 million US prescriptions since January, showing strong demand for weight-loss drugs
The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful...
